SCHEMBL13420519

SCHEMBL13420519

CC(=O)O[C@H]1CC[C@]23CC24CC[C@]2(C)[C@@H]([C@H](C)CCC(=O)C(C)C)CC[C@@]2(C)[C@@H]4CC[C@H]3C1(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 2/20 0.54
▸ ACACA Q13085 2/20 0.54
▸ PTPN11 Q06124 1/20 0.53
▸ HSD11B1 P28845 9/20 0.45
▸ HSD11B2 P80365 2/20 0.45
▸ NR3C1 P04150 1/20 0.45
▸ NR3C2 P08235 1/20 0.45
▸ HSD17B2 P37059 1/20 0.45
▸ USP2 O75604 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ PSEN1 P49768 1/20 0.40
▸ PSEN2 P49810 1/20 0.40
▸ APH1B Q8WW43 1/20 0.40
▸ NCSTN Q92542 1/20 0.40
▸ APH1A Q96BI3 1/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13420699 1.00 ACLY (0.54) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420438 1.00 ACLY (0.54) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420204 1.00 ACLY (0.54) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL14046874 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420207 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420408 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420517 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420592 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420516 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL13420437 0.91 ACLY (0.57) ACLYACACAPTPN11HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056487-A1 MODULATORS OF AMYLOID-BETA PRODUCTION SATORI PHARMACEUTICALS, INC. (US) 2010-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056487-A1 MODULATORS OF AMYLOID-BETA PRODUCTION APP, BACE1, BACE2 ACLY 668/4885ACACA 195/4885PTPN11 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback